Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers

• Published in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 28; no. 6; pp. 791 - 796
• Main Authors: Yamazaki, Shingo, Watanabe, Kenta, Okuda, Yoshio, Urushihara, Misao, Koshikawa, Hiromi, Chiba, Hitoshi, Yahaba, Misuzu, Taniguchi, Toshibumi, Nakada, Taka-aki, Nakajima, Hiroshi, Ishii, Itsuko, Igari, Hidetoshi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.06.2022; Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd
• Subjects: Adverse event; Application software; COVID-19 - prevention & control; COVID-19 Vaccines - adverse effects; Drug-Related Side Effects and Adverse Reactions; Health Personnel; Humans; Original; SARS-CoV-2; SARS-CoV2; Software; Vaccination - adverse effects; Vaccine; Adverse event; SARS-CoV2; Vaccine; Application software
• ISSN: 1341-321X; 1437-7780
• DOI: 10.1016/j.jiac.2022.02.020

The usefulness of smartphone-based application software as a way to manage adverse events (AEs) after vaccination is well known. The purpose of this study is to clarify the usefulness and precautions of employing a smartphone application for collecting AEs after the administration of Comirnaty®️. Healthcare workers (HCWs) who were vaccinated with Comirnaty®️ were asked to register for the application software and to report AEs for 14 days after vaccination. AEs were self-reported according to severity. The software was set to output an alert in case of fever. The number of HCWs who received the first dose was 2,551, and 2,406 (94.3%) reported their vaccinations. 2,547 received the second dose, and 2,347 (92.1%) reported their vaccinations. With the first dose, the reporting rate stayed above 83.3% until the final day. On the other hand, that of the second dose decreased rapidly after 6 days. The most frequent symptom was “pain at injection site” (more than 70%). Severe AEs were 6.6% after the second dose, with 0.6% visiting a clinic. Many AEs peaked on the day after administration and disappeared within 1 week. There were few reports of fever. Smartphone applications can be used to collect information on AEs after vaccination. Application settings and dissemination are necessary to maintain the reporting rate of HCWs.